Novo Nordisk Provides Update on Share Repurchase Program
Novo Nordisk disclosed the status of its ongoing share repurchase program, reporting that it has repurchased 42,604,179 B shares as of 6 November 2026.
Stocks · News reference
Novo Nordisk Upgrades Metabolic Health Service 'Lightweight Station' in China
Novo Nordisk announced the upgrade of its 'Lightweight Station' metabolic health service in retail pharmacies across China to provide enhanced weight management and metabolic health support.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
Pfizer plans to enter the GLP-1 market in 2028 with berobenatide, acquired through its Metsera purchase. Despite a late entry compared to competitors, Pfizer believes its strong commercial execution capabilities, operational scale, and expertise in rapid product rollout (demonstrated with COVID vaccine/pill) position it to become a market leader in the projected $190 billion GLP-1 market by 2035.
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists Due to Potential Increased Risk of Rare But Serious Eye Condition
Eli Lilly Gains After Jefferies Raises Price Target to Wall Street-High $1,700
Eli Lilly is rising Monday after Jefferies raised its price target to $1,700, the highest target on Wall Street, according to Investing.com.
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.
Eli Lilly's market capitalization has grown to nearly 9 times that of Novo Nordisk, driven by their dominance in the GLP-1 weight loss drug market. Lilly captured 63% U.S. market share by early 2025 compared to Novo's 36%, aided by superior manufacturing infrastructure, greater weight loss efficacy of tirzepatide (20% vs. 14%), and advantages of its oral drug Foundayo. Meanwhile, Novo faced setbacks including mixed data on CagriSema and a failed heart drug trial.
Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?
Novo Nordisk's Wegovy GLP-1 weight-loss pill has surpassed 5 million prescriptions and is outperforming the company's injectable version, supporting its strategic shift to a volume-driven business model. However, the company faces headwinds from lower pricing, weak earnings, and intensifying competition from Eli Lilly's rival GLP-1 pill. The stock offers an attractive 4.4% dividend yield and historically cheap valuation, making it appealing for aggressive dividend investors willing to bet on the turnaround, though more conservative investors should wait for clearer progress on profitability.